MX2009005984A - Formulaciones con alta concentracion de proteina que contiene manitol. - Google Patents

Formulaciones con alta concentracion de proteina que contiene manitol.

Info

Publication number
MX2009005984A
MX2009005984A MX2009005984A MX2009005984A MX2009005984A MX 2009005984 A MX2009005984 A MX 2009005984A MX 2009005984 A MX2009005984 A MX 2009005984A MX 2009005984 A MX2009005984 A MX 2009005984A MX 2009005984 A MX2009005984 A MX 2009005984A
Authority
MX
Mexico
Prior art keywords
protein concentration
formulations containing
high protein
containing mannitol
concentration formulations
Prior art date
Application number
MX2009005984A
Other languages
English (en)
Inventor
David Christopher Sek
Kin Ho
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2009005984A publication Critical patent/MX2009005984A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona un método para inhibir agregación inducida por manitol de una proteína en una formulación líquida al incrementar la concentración de proteína a una cantidad mayor de 50 mg/ml. La presente invención también proporciona métodós para almacenar y preparar una formulación líquida que contiene manitol y una concentración de proteína mayor de 50 mg/ml.
MX2009005984A 2006-12-06 2007-12-05 Formulaciones con alta concentracion de proteina que contiene manitol. MX2009005984A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87352606P 2006-12-06 2006-12-06
PCT/US2007/086507 WO2008070721A2 (en) 2006-12-06 2007-12-05 High protein concentration formulations containing mannitol

Publications (1)

Publication Number Publication Date
MX2009005984A true MX2009005984A (es) 2009-06-16

Family

ID=39493053

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005984A MX2009005984A (es) 2006-12-06 2007-12-05 Formulaciones con alta concentracion de proteina que contiene manitol.

Country Status (13)

Country Link
US (1) US20080139792A1 (es)
EP (1) EP2089001A2 (es)
JP (1) JP2010512336A (es)
KR (1) KR20090086632A (es)
CN (1) CN101631535A (es)
AU (1) AU2007329333A1 (es)
BR (1) BRPI0720125A2 (es)
CA (1) CA2671571A1 (es)
IL (1) IL198977A0 (es)
MX (1) MX2009005984A (es)
RU (1) RU2009120200A (es)
WO (1) WO2008070721A2 (es)
ZA (1) ZA200903953B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
CA2707483A1 (en) * 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
JP2011520889A (ja) * 2008-05-15 2011-07-21 バクスター・インターナショナル・インコーポレイテッド 安定な医薬製剤
NZ592644A (en) * 2008-11-28 2013-09-27 Abbott Lab Stable antibody compositions and methods for stabilizing same
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
KR20120038406A (ko) * 2009-05-04 2012-04-23 애보트 바이오테크놀로지 리미티드 인간 항?ＴＮＦ?α 항체의 안정한 고 단백질 농도 제형
PL3438126T3 (pl) 2009-09-03 2021-03-08 Ablynx N.V. Stabilne formulacje polipeptydów i ich zastosowanie
WO2016202713A1 (en) * 2015-06-15 2016-12-22 F. Hoffmann-La Roche Ag Method of freezing protein solutions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA902663B (en) * 1989-04-07 1991-12-24 Syntex Inc Interleukin-1 formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
MXPA04000747A (es) * 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
WO2004055164A2 (en) * 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
WO2006014965A2 (en) * 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Pharmaceutical formulation and process

Also Published As

Publication number Publication date
IL198977A0 (en) 2010-02-17
CA2671571A1 (en) 2008-06-12
US20080139792A1 (en) 2008-06-12
ZA200903953B (en) 2010-03-31
RU2009120200A (ru) 2011-01-20
KR20090086632A (ko) 2009-08-13
WO2008070721A2 (en) 2008-06-12
WO2008070721A3 (en) 2008-09-18
CN101631535A (zh) 2010-01-20
EP2089001A2 (en) 2009-08-19
BRPI0720125A2 (pt) 2014-01-28
JP2010512336A (ja) 2010-04-22
AU2007329333A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
MX2009005984A (es) Formulaciones con alta concentracion de proteina que contiene manitol.
NZ605873A (en) Methods and compositions for cns delivery of arylsulfatase a
MX2009006594A (es) Formulaciones de ph regulado y estables que contienen polipeptidos.
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
MY161991A (en) Proteasome inhibitors
EP4233892A3 (en) Stable anti-ifnar1 formulation
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
MX2009008769A (es) Formulaciones de proteina que contienen sorbitol.
BRPI0615265A8 (pt) composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
MX2010004389A (es) Formulaciones de vancomicina liposomales.
NZ702808A (en) Methods and compositions for cns delivery of iduronate-2-sulfatase
MY155592A (en) Boronate ester compounds and pharmaceutical compositions thereof
MX2014000468A (es) Composiciones plaguicidas y procesos relacionados.
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
PL1730147T3 (pl) Podstawowe związki 1,4,8-triazaspiro[4.5]dekan-2-onu
WO2009114725A3 (en) Mobilization op hematopoietic stem cells using cdc42 inhibitors
TW200603790A (en) Composition for acceleration of alcohol metabolism or recuperation from fatigue through gluconeogenesis
NZ702342A (en) Pharmaceutical formulation
TNSN07435A1 (en) Novel piperidine carboxylic acid amide derivatives
SI1730144T1 (sl) Substituirane spojine 1,4,8-triazaspiro(4.5)dekan-2-on
TW200621773A (en) Bicyclononene derivatives
TW200738714A (en) New secondary amines
MX2015005237A (es) Formulacion liquida que comprende un compuesto neutralizante de gm-csf.
TW200510404A (en) Novel 8-aza-bicyclo[3.2.1] octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
UA107487C2 (uk) Склад для профілактики кандидозів

Legal Events

Date Code Title Description
FA Abandonment or withdrawal